The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic review
Asthma is a complex, chronic inflammatory condition of the airways that comes in many forms. Because different inflammatory processes drive it, we can generally categorize asthma into two main types: type 2 inflammatory asthma and non-type 2 inflammatory asthma. Type 2 inflammation is usually the cu...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531986/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850150530581528576 |
|---|---|
| author | Junhui Ma Qiang Ma Jing Yang Panpan Liang Jiaxin Zhou Jiarui Ma Fuhua Ma Bing Zhuan Wei Zhou |
| author_facet | Junhui Ma Qiang Ma Jing Yang Panpan Liang Jiaxin Zhou Jiarui Ma Fuhua Ma Bing Zhuan Wei Zhou |
| author_sort | Junhui Ma |
| collection | DOAJ |
| description | Asthma is a complex, chronic inflammatory condition of the airways that comes in many forms. Because different inflammatory processes drive it, we can generally categorize asthma into two main types: type 2 inflammatory asthma and non-type 2 inflammatory asthma. Type 2 inflammation is usually the culprit in most folks grappling with severe asthma. There is a noticeable difference in the treatment approaches for different phenotypes of severe asthma. The main reason is that patients suffering from type 2 inflammatory asthma can respond well to treatment with biological agents. Several well-verified biological agents, such as anti-immunoglobulin E (IgE) monoclonal antibodies, anti-interleukin (IL)-4 monoclonal antibodies, anti-IL-5 monoclonal antibodies, and anti-thymic stromal lymphopoietin (TSLP) monoclonal antibodies, have shown outstanding effectiveness. They can significantly alleviate asthma exacerbations, lower the number of eosinophils, improve pulmonary function, decrease the dependence on oral corticosteroids, and elevate the quality of life for patients with asthma. This discourse meticulously evaluates the therapeutic prowess of biological agents in the treatment and control of severe asthma, concurrently investigating their impact on histological indices, to highlight the crucial role of precision medicine in the strategic concatenation of therapy for this refractory malady. |
| format | Article |
| id | doaj-art-a08eac4251c44f8fa7891ad200cacb7b |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-a08eac4251c44f8fa7891ad200cacb7b2025-08-20T02:26:31ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-04-011610.3389/fimmu.2025.15319861531986The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic reviewJunhui Ma0Qiang Ma1Jing Yang2Panpan Liang3Jiaxin Zhou4Jiarui Ma5Fuhua Ma6Bing Zhuan7Wei Zhou8Department of Respiratory Medicine, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, Ningxia, ChinaDepartment of Chest Surgery, People’s Hospital of Ningxia Hui Autonomous Region, Yinchuan, ChinaDepartment of Respiratory Medicine, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, Ningxia, ChinaDepartment of Respiratory Medicine, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, Ningxia, ChinaDepartment of Respiratory Medicine, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, Ningxia, ChinaDepartment of Respiratory Medicine, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, Ningxia, ChinaMedical Administration Department, Yongning County People’s Hospital, Yinchuan, ChinaDepartment of Respiratory Medicine, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, Ningxia, ChinaDepartment of Respiratory Medicine, People's Hospital of Ningxia Hui Autonomous Region, Ningxia Medical University, Yinchuan, Ningxia, ChinaAsthma is a complex, chronic inflammatory condition of the airways that comes in many forms. Because different inflammatory processes drive it, we can generally categorize asthma into two main types: type 2 inflammatory asthma and non-type 2 inflammatory asthma. Type 2 inflammation is usually the culprit in most folks grappling with severe asthma. There is a noticeable difference in the treatment approaches for different phenotypes of severe asthma. The main reason is that patients suffering from type 2 inflammatory asthma can respond well to treatment with biological agents. Several well-verified biological agents, such as anti-immunoglobulin E (IgE) monoclonal antibodies, anti-interleukin (IL)-4 monoclonal antibodies, anti-IL-5 monoclonal antibodies, and anti-thymic stromal lymphopoietin (TSLP) monoclonal antibodies, have shown outstanding effectiveness. They can significantly alleviate asthma exacerbations, lower the number of eosinophils, improve pulmonary function, decrease the dependence on oral corticosteroids, and elevate the quality of life for patients with asthma. This discourse meticulously evaluates the therapeutic prowess of biological agents in the treatment and control of severe asthma, concurrently investigating their impact on histological indices, to highlight the crucial role of precision medicine in the strategic concatenation of therapy for this refractory malady.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531986/fullsevere asthmatype 2 inflammationbiologic therapypathological histology efficacyphenotype |
| spellingShingle | Junhui Ma Qiang Ma Jing Yang Panpan Liang Jiaxin Zhou Jiarui Ma Fuhua Ma Bing Zhuan Wei Zhou The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic review Frontiers in Immunology severe asthma type 2 inflammation biologic therapy pathological histology efficacy phenotype |
| title | The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic review |
| title_full | The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic review |
| title_fullStr | The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic review |
| title_full_unstemmed | The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic review |
| title_short | The clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation - systematic review |
| title_sort | clinical and pathological histology efficacy of biological therapy for severe asthma with a phenotype of type 2 inflammation systematic review |
| topic | severe asthma type 2 inflammation biologic therapy pathological histology efficacy phenotype |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1531986/full |
| work_keys_str_mv | AT junhuima theclinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT qiangma theclinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT jingyang theclinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT panpanliang theclinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT jiaxinzhou theclinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT jiaruima theclinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT fuhuama theclinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT bingzhuan theclinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT weizhou theclinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT junhuima clinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT qiangma clinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT jingyang clinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT panpanliang clinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT jiaxinzhou clinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT jiaruima clinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT fuhuama clinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT bingzhuan clinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview AT weizhou clinicalandpathologicalhistologyefficacyofbiologicaltherapyforsevereasthmawithaphenotypeoftype2inflammationsystematicreview |